{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Any changes to the scheduled dosing interval (q3W) or adjustments in the infusion rate should', 'be reported to the Sponsor/CRO.', '9.4.7 Method of Assigning Subjects to Treatment Groups', 'A randomization schedule will be generated by the CRO prior to shipment of any study drug to', 'the clinical sites. On Day 1 of the double-masked Treatment Period, once all Baseline procedures', 'other than administration of drug have been completed, the masked site personnel will use the', 'IWRS to randomize the subject. The unmasked pharmacist or designee will then use the IWRS to', 'obtain dosing information, and dispense the appropriate study drug.', '9.4.8 Masking and Unmasking', 'The pharmacists or designees responsible for preparing the teprotumumab or placebo solutions', 'for IV administration will not be masked to the identity of the study drug. Pharmacists/designees', 'will provide study drug in infusion bags (fully diluted for administration) to study site personnel', 'with appropriate masked labels. The subject, Investigator, and all other study site personnel will', 'be masked to the treatment being administered.', 'During the phase 2 TED01RV trial, hyperglycemia was the only laboratory finding and adverse', 'event clearly identified by the Investigators as being related to teprotumumab. Furthermore,', 'hyperglycemia was observed in both treatment groups, placebo and teprotumumab. Given the', 'occurrence of this event in both treatment groups, it is not possible to determine the identity of', 'the masked study product based on the occurrence of this particular event.', 'The study mask should be broken only if the safety of a subject is at risk and the treatment plan', 'depends on which medication he or she received. Unless the subject is at immediate risk, the', \"Investigator must make diligent attempts to contact the Sponsor or Sponsor's designee before\", \"unmasking the subject's data. If a subject's data are unmasked without prior knowledge of the\", 'Sponsor, the Investigator must notify the Sponsor as soon as possible and no later than the next', 'business day. All circumstances surrounding the event must be clearly documented.', \"The Sponsor's Pharmacovigilance department or designee will unmask the identity of the study\", 'medication for an unexpected, drug-related SAE for submission to health authorities and', 'IRB/IEC according to applicable regulatory requirements. However, the results will not be', 'shared with other Sponsor representatives or staff at study sites. Details of subjects who are', 'unmasked during the study will be included in the Clinical Study Report.', 'Unmasking for independent pharmacological analysis of biological samples or SAE reporting', 'will be performed according to procedures in place to ensure integrity of the data.', 'All investigative site staff directly involved in this study will remain masked from Screening', 'through analysis of the Follow-Up data and all site close-out visits. The Sponsor and its', 'designees will be unmasked after the database lock following completion of all subjects in the', 'double-masked treatment phase.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 75 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.4.9 Concomitant Therapy and Restricted Medications', 'Local supportive measures for TED, simple analgesics (e.g., acetaminophen, non-steroidal', 'anti-inflammatory therapies), and medications/supplements for conditions other than TED are', 'permitted during the study. Topical corticosteroids for conditions other than TED are allowed;', 'however, oral corticosteroid use during the study is restricted to subjects who experience', 'infusion-associated AEs.', 'Symptomatic treatment (e.g., antipyretics, antihistamines, beta-agonists, oxygen, IV fluid) may', 'be administered to subjects who experience immediate infusion-associated AEs. Following the', 'appearance of either immediate or delayed infusion-associated events, subsequent dosing of', 'study drug may be pre-treated with diphenhydramine (1 to 1.25 mg/kg IV; maximum of 50 mg),', 'ranitidine (50 mg IV), famotidine (0.5 mg/kg IV), dexamethasone (0.4 mg/kg IV; maximum of', '20 mg), and/or acetaminophen (500 mg).', '9.4.9.1 Restricted Therapy and Medications', 'Subjects with a previous orbital irradiation or surgery for TED or who have a planned orbital', 'irradiation or surgery for TED over the course of this study are not eligible for study enrollment.', 'In addition, oral corticosteroids, selenium, biotin, immunosuppressive agents, investigational', 'agents, and illicit drug/alcohol use are restricted as shown in Table 9.1.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 76 of 117']\n\n###\n\n", "completion": "END"}